A recent study indicates that women who begin hormone replacement therapy (HRT) at a particular age may experience a lower risk of developing dementia. The research, published in the journal Alzheimer’s & Dementia, examined data from the UK Biobank involving 183,450 postmenopausal women with an average age of 60.
The findings reveal that using HRT might be linked to approximately a 10% reduction in the overall risk of dementia and a 16% decrease in the risk of Alzheimer’s disease over a span of 13 years. Notably, the reduction in risk was most significant among women who started therapy between the ages of 46 and 56, as well as those who underwent surgical menopause. However, starting HRT after the age of 56 did not show a similar benefit.
Dr. Alexa Fiffick, a family medicine physician based in Cleveland, Ohio, pointed out that this research is observational and cannot definitively prove that HRT prevents dementia. She noted, “We can’t say for sure that it makes a difference.”
The study’s limitations include its inability to assess safety outcomes or potential side effects of HRT. Researchers noted that women who opt for HRT may have different health profiles compared to non-users, including lifestyle and access to healthcare, which could also influence dementia risk.
Many participants in the study were of European descent and generally better off financially, raising questions about how applicable the findings are to diverse populations. Dr. Fiffick emphasized that this study alone should not prompt women to seek HRT solely for dementia prevention but encouraged those experiencing menopausal symptoms to discuss their concerns with healthcare providers.
She added, “If you’re having symptoms, if you feel not yourself, talk to your doctor.” While some research suggests that menopausal symptoms like hot flashes may be related to changes in brain health, more data is needed to confirm whether treating these symptoms can prevent dementia.
HRT does have known risks, including a heightened chance of blood clots with oral estrogen, although risks seem lower with transdermal options like patches and creams. Dr. Fiffick cautioned that HRT’s effects can vary widely among individuals and highlighted the importance of thorough discussions with doctors about potential treatments.
Looking towards the future, researchers in the UK plan to conduct randomized controlled trials to further investigate the impact of HRT on dementia risk, taking various factors into account, such as the type of hormone therapy, dosage, and timing of treatment initiation.
Dr. Fiffick expressed optimism, stating, “Women deserve information to make informed choices about their health.” With ongoing studies, strides can be made to provide clearer guidelines for women considering HRT.
